Loading clinical trials...
Loading clinical trials...
Modulation of ∆9-tetrahydrocannabinol Acute Psychoactive Effects by Ranging Doses of Cannabidiol in Healthy, Occasional Cannabis Users: a Controlled, Triple Blind, Randomized, Cross-over Study
Conditions
Interventions
∆9-tetrahydrocannabinol
Locations
1
Canada
Centre de recherche du Centre Hospitalier Universitaire de Montréal
Montreal, Quebec, Canada
Start Date
June 27, 2024
Primary Completion Date
July 31, 2026
Completion Date
December 31, 2026
Last Updated
December 22, 2025
NCT05602649
NCT04810858
NCT05855668
NCT06878859
NCT07196462
NCT07417059
Lead Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions